Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01685411 · ClinicalTrials.gov registry record · NA
Busulfan and Cyclophosphamide Followed By ALLO BMT
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01685411: Clinical Trial NA study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT01685411 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01685411, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
Primary Outcome
The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works. Patients with leukemia involving the BM and myelodysplastic syndrome will have this assessed by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients will also have radiology studies such as plain X-rays
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Allopurinol
- DRUG Tacrolimus
- DRUG Keppra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-01 |
| Est. Completion | 2020-02-10 |
| Phase | NA |
Why NCT01685411 stopped before completion
NCT01685411 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01685411 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01685411 about?
NCT01685411 is a clinical study titled "Busulfan and Cyclophosphamide Followed By ALLO BMT". This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
What is the current status of trial NCT01685411?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2013-01. Estimated completion is 2020-02-10.
What interventions are being tested in trial NCT01685411?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Allopurinol (DRUG), Tacrolimus (DRUG), Keppra (DRUG).
Who is sponsoring clinical trial NCT01685411?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01685411's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia